PharmaTelevision - Telormedix’s program around Toll-like receptor 7 and the clinical developments for the localized treatment of bladder cancer.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Telormedix’s program around Toll-like receptor 7 and the clinical developments for the localized treatment of bladder cancer.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Johanna Holldack, CEO of Telormedix

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Lead compound and formulation technology

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I have Johanna Holldack, who is CEO of the company called Telormedix based in Switzerland, welcome to the show.

Johanna Holldack:

Thank you very much.

Fintan Walton:

Johanna Holldack, your company is a relatively new company, it was founded in 2007 it's based in Switzerland, tell us about the company Telormedix?

Johanna Holldack:

Well you know in a way it's a really unique company, first of all at the very beginning it raised one of the biggest rounds A rounds in Europe with 21 million Swiss Franc and that allowed us to develop our lead compound and it allowed us to build a portfolio, and we are kind of proud to say that only after two and a half years we have been able to move our first compound into clinical development, so we started at the beginning of this year a Phase I/II clinical trial in bladder cancer and we have treated the first patients and it's going really well and of course that is a key value driver. So we are young biotech company, but we have already a compound in clinical trials and we are building a portfolio.

Fintan Walton:

Okay, so let's just look at structure of this, so first of all tell us little bit more about the products that you've got going into clinical trials or is in clinical trials, because it's from an existing product that you've reformulated, tell us about that story?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Johanna Holldack

Chief Executive Officer

Dr. Johanna Holldack , has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma. Dr. Johanna Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Telormedix

Telormedix is a clinical stage biopharmaceutical company founded in 2007 and focused on targeted immunity in the treatment of cancer and other diseases. The Company's lead product, TMX-101, is currently investigated in a clinical trial for the localized treatment of bladder cancer, a disease of unmet medical need. TMX-101 is a new formulation of a clinically active small molecule compound specifically optimized for treating bladder cancer. Telormedix also has an additional pipeline of product candidates targeting cancer and autoimmune diseases. The Company's discovery capability, managed under an exclusive licensing agreement, draws on years of experience and the world class research standing of its academic partner. Located in Switzerland, Telormedix is led by a highly experienced management team and is privately held, backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland), Proquest Investments (Princeton-San Diego, USA), BSI S.A. (Lugano, Switzerland), Nextech Venture (Zurich Switzerland) and Generali Insurance Group (Italy).